- In August 2024, Certara, Inc., a global leader in model-informed drug development, launched Phoenix version 8.5, a leading pharmacokinetic/pharmacodynamic (PK/PD) and toxicokinetic modeling and simulation software widely regarded as the industry standard. Used by over 75 of the top 100 pharmaceutical companies worldwide, Phoenix’s updated platform strengthens Certara’s position in the biosimulation market by enhancing drug development accuracy and efficiency
- In June 2024, Simulations Plus expanded its market presence by acquiring Pro-ficiency, enabling the integration of Pro-ficiency’s innovative software solutions with its existing platforms. This strategic move is expected to create a comprehensive biosimulation platform that streamlines and optimizes drug development, strengthening Simulations Plus’s competitive position in the market
- In December 2023, Certara broadened its biosimulation portfolio through the acquisition of Applied Biomath, a leader in model-informed drug discovery. This acquisition enhances Certara’s capabilities in early-stage drug development, reinforcing its market leadership and ability to offer end-to-end simulation solutions
- In November 2023, Certara launched the Simcyp Biopharmaceutics software, aimed at improving the efficiency of both novel and generic drug formulation development. This product launch positions Certara to better address industry needs for faster, more cost-effective formulation strategies, thereby driving increased adoption of biosimulation technologies
- In June 2023, Simulations Plus further strengthened its foothold in specialized therapeutic areas by acquiring Immunetrics, a company focused on modeling and simulation for oncology, immunology, and autoimmune diseases. This acquisition expands Simulations Plus’s market reach and expertise, catering to growing demand for biosimulation in complex disease research
